QQQ   355.04 (+0.23%)
AAPL   170.43 (-0.89%)
MSFT   312.79 (+0.21%)
META   297.74 (-0.41%)
GOOGL   130.54 (+1.54%)
AMZN   125.98 (+0.00%)
TSLA   240.50 (-1.48%)
NVDA   424.68 (+1.33%)
NIO   8.46 (+0.59%)
BABA   86.19 (+0.33%)
AMD   98.07 (+2.20%)
T   14.87 (-1.00%)
F   12.39 (-0.32%)
MU   68.21 (+0.40%)
CGC   0.89 (-3.49%)
GE   110.89 (+0.87%)
DIS   79.90 (-0.19%)
AMC   7.57 (-4.30%)
PFE   32.10 (-0.93%)
PYPL   57.34 (-2.70%)
NFLX   377.59 (-0.44%)
QQQ   355.04 (+0.23%)
AAPL   170.43 (-0.89%)
MSFT   312.79 (+0.21%)
META   297.74 (-0.41%)
GOOGL   130.54 (+1.54%)
AMZN   125.98 (+0.00%)
TSLA   240.50 (-1.48%)
NVDA   424.68 (+1.33%)
NIO   8.46 (+0.59%)
BABA   86.19 (+0.33%)
AMD   98.07 (+2.20%)
T   14.87 (-1.00%)
F   12.39 (-0.32%)
MU   68.21 (+0.40%)
CGC   0.89 (-3.49%)
GE   110.89 (+0.87%)
DIS   79.90 (-0.19%)
AMC   7.57 (-4.30%)
PFE   32.10 (-0.93%)
PYPL   57.34 (-2.70%)
NFLX   377.59 (-0.44%)
QQQ   355.04 (+0.23%)
AAPL   170.43 (-0.89%)
MSFT   312.79 (+0.21%)
META   297.74 (-0.41%)
GOOGL   130.54 (+1.54%)
AMZN   125.98 (+0.00%)
TSLA   240.50 (-1.48%)
NVDA   424.68 (+1.33%)
NIO   8.46 (+0.59%)
BABA   86.19 (+0.33%)
AMD   98.07 (+2.20%)
T   14.87 (-1.00%)
F   12.39 (-0.32%)
MU   68.21 (+0.40%)
CGC   0.89 (-3.49%)
GE   110.89 (+0.87%)
DIS   79.90 (-0.19%)
AMC   7.57 (-4.30%)
PFE   32.10 (-0.93%)
PYPL   57.34 (-2.70%)
NFLX   377.59 (-0.44%)
QQQ   355.04 (+0.23%)
AAPL   170.43 (-0.89%)
MSFT   312.79 (+0.21%)
META   297.74 (-0.41%)
GOOGL   130.54 (+1.54%)
AMZN   125.98 (+0.00%)
TSLA   240.50 (-1.48%)
NVDA   424.68 (+1.33%)
NIO   8.46 (+0.59%)
BABA   86.19 (+0.33%)
AMD   98.07 (+2.20%)
T   14.87 (-1.00%)
F   12.39 (-0.32%)
MU   68.21 (+0.40%)
CGC   0.89 (-3.49%)
GE   110.89 (+0.87%)
DIS   79.90 (-0.19%)
AMC   7.57 (-4.30%)
PFE   32.10 (-0.93%)
PYPL   57.34 (-2.70%)
NFLX   377.59 (-0.44%)
NASDAQ:RGLS

Regulus Therapeutics (RGLS) Earnings Date, Estimates & Call Transcripts

$1.36
0.00 (0.00%)
(As of 04:26 PM ET)
Compare
Today's Range
$1.26
$1.41
50-Day Range
$1.27
$1.76
52-Week Range
$0.76
$2.14
Volume
30,778 shs
Average Volume
46,503 shs
Market Capitalization
$26.49 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.50

Earnings Summary

Upcoming
Earnings Date
Nov. 9Estimated
Actual EPS
(Aug. 8)
-$0.37 Beat By $0.02
Consensus EPS
(Aug. 8)
-$0.39
Skip Charts & View Estimated and Actual Earnings Data

RGLS Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

RGLS Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Regulus Therapeutics Analyst Forecasts

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20231($0.39)($0.39)($0.39)
Q3 20231($0.36)($0.36)($0.36)
Q4 20231($0.38)($0.38)($0.38)
20233($1.13)($1.13)($1.13)
Q1 20241($0.34)($0.34)($0.34)
Q2 20241($0.30)($0.30)($0.30)
Q3 20241($0.29)($0.29)($0.29)
Q4 20241($0.27)($0.27)($0.27)
FY 20244($1.20)($1.20)($1.20)

RGLS Earnings Date and Information

Regulus Therapeutics last released its quarterly earnings data on August 8th, 2023. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.39) by $0.02. Regulus Therapeutics has generated ($1.69) earnings per share over the last year (($1.69) diluted earnings per share). Earnings for Regulus Therapeutics are expected to grow in the coming year, from ($1.52) to ($1.19) per share. Regulus Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, November 9th, 2023 based off prior year's report dates.

Regulus Therapeutics Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
11/9/2023
Estimated)
------- 
8/8/2023Q2 2023($0.39)($0.37)+$0.02($0.37)--
5/11/2023Q1 2023($0.41)($0.42)($0.01)($0.42)--
3/23/2023Q4 2022($0.49)($0.40)+$0.09($0.40)--
11/10/2022Q3 2022($0.50)($0.50)-($0.50)--
8/11/2022Q2 2022($0.46)($0.50)($0.04)($0.50)--
5/12/2022Q1 2022($0.50)($0.50)-($0.05)--    
3/10/2022Q4 2021($0.50)($0.70)($0.20)($0.07)--    
11/10/2021Q3 2021($0.80)($1.00)($0.20)($0.10)--    
8/10/2021Q2 2021($0.80)($0.80)-($0.08)--    
5/13/2021Q1 2021($0.90)($0.80)+$0.10($0.08)--  
3/8/2021Q4 2020($1.40)($0.30)+$1.10($0.03)$0.02 million$5.00 million
11/5/2020Q3 2020($2.10)($0.40)+$1.70($0.04)$0.51 million$5.00 million  












Regulus Therapeutics Earnings - Frequently Asked Questions

When is Regulus Therapeutics's earnings date?

Regulus Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, November 9th, 2023 based off last year's report dates. Learn more on RGLS's earnings history.

Did Regulus Therapeutics beat their earnings estimates last quarter?

In the previous quarter, Regulus Therapeutics (NASDAQ:RGLS) reported ($0.37) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.39) by $0.02. Learn more on analysts' earnings estimate vs. RGLS's actual earnings.

How much revenue does Regulus Therapeutics generate each year?

Regulus Therapeutics (NASDAQ:RGLS) has a recorded annual revenue of $10.01 million.

How much profit does Regulus Therapeutics generate each year?

Regulus Therapeutics (NASDAQ:RGLS) has a recorded net income of -$28.32 million. RGLS has generated -$1.69 earnings per share over the last four quarters.

What is Regulus Therapeutics's EPS forecast for next year?

Regulus Therapeutics's earnings are expected to grow from ($1.52) per share to ($1.19) per share in the next year.


More Earnings Resources from MarketBeat

This page (NASDAQ:RGLS) was last updated on 9/27/2023 by MarketBeat.com Staff

My Account -